Faecal calprotectin in suspected paediatric inflammatory bowel disease.
OBJECTIVE
The diagnostic accuracy of faecal calprotectin (FC) concentration for paediatric inflammatory bowel disease (IBD) is well described at the population level, but not at the individual level. We reassessed the diagnostic accuracy of FC in children with suspected IBD and developed an individual risk prediction rule using individual patient data.


METHODS
MEDLINE, EMBASE, DARE, and MEDION databases were searched to identify cohort studies evaluating the diagnostic performance of FC in paediatric patients suspected of having IBD. A standard study-level meta-analysis was performed. In an individual patient data meta-analysis, we reanalysed the diagnostic accuracy on a merged patient dataset. Using logistic regression analysis we investigated whether and how the FC value and patient characteristics influence the diagnostic precision. A prediction rule was derived for use in clinical practice and implemented in a spreadsheet calculator.


RESULTS
According to the study-level meta-analysis (9 studies, describing 853 patients), FC has a high overall sensitivity of 0.97 (95% confidence interval [CI] 0.92-0.99) and a specificity of 0.70 (0.59-0.79) for diagnosing IBD. In the patient-level pooled analysis of 742 patients from 8 diagnostic accuracy studies, we calculated that at an FC cutoff level of 50 μg/g there would be 17% (95% CI 15-20) false-positive and 2% (1-3) false-negative results. The final logistic regression model was based on individual data of 545 patients and included both FC level and age. The area under the receiver operating characteristic curve of this derived prediction model was 0.92 (95% CI 0.89-0.94).


CONCLUSIONS
In high-prevalence circumstances, FC can be used as a noninvasive biomarker of paediatric IBD with only a small risk of missing cases. To quantify the individual patients' risk, we developed a simple prediction model based on FC concentration and age. Although the derived prediction rule cannot substitute the clinical diagnostic process, it can help in selecting patients for endoscopic evaluation.
*Department of Paediatrics, Maastricht University Medical Centre, Maastricht, The Netherlands †Department of Paediatrics, Tampere University Hospital, Tampere, Finland ‡Department of Paediatrics and European Laboratory for the Investigation of Food Induced Diseases, University of Naples "Federico II," Naples, Italy §Paediatric Gastroenterology, Sydney Children's Hospital, Randwick, Australia ¶Hepathology, Gastroenterology and Nutrition Unit, Bambino Gesù Children's Hospital, Rome, Italy #Department of Paediatrics, Centre for Clinical Research, Västmanlands Hospital, Västerås, Karolinska Institutet, Stockholm, Sweden **Department of Paediatric Gastroenterology and Nutrition, Royal Hospital for Sick Children ‡‡Hospital for Children and Adolescents, University of Helsinki, Helsinki, Finland §§Department of Paediatrics, University Hospital Antwerp, Edegem, Belgium ||||Department of Paediatric Gastroenterology, University of Groningen, University Medical Centre Groningen ¶¶Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Centre, Maastricht, The Netherlands.
Pieter L J
PL
Degraeuwe
Monique P A
MP
Beld
Merja
M
Ashorn
Roberto Berni
RB
Canani
Andrew S
AS
Day
Antonella
A
Diamanti
Ulrika L
UL
Fagerberg
Paul
P
Henderson
Kaija-Leena
KL
Kolho
Els
E
Van de Vijver
Patrick F
PF
van Rheenen
David C
DC
Wilson
Alfons G H
AG
Kessels
D000293:Adolescent; D015415:Biomarkers / Q000032:analysis; D002648:Child; D015331:Cohort Studies; D005243:Feces / Q000737:chemistry*; D006801:Humans; D007223:Infant; D015212:Inflammatory Bowel Diseases / Q000175:diagnosis* / Q000453:epidemiology / Q000378:metabolism; D039841:Leukocyte L1 Antigen Complex / Q000032:analysis* / Q000378:metabolism; D016015:Logistic Models; D057285:Precision Medicine; D012306:Risk; D012680:Sensitivity and Specificity
D015415:Biomarkers; D039841:Leukocyte L1 Antigen Complex